Transforming growth factor-beta-1 genetic polymorphism in Japanese patients with chronic hepatitis C virus infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 10, 2003, Pages 1139-1143

  Suzuki, Seiji ^a   Tanaka, Yasuhito ^a   Orito, Etsuro ^a   Sugauchi, Fuminaka ^a   Hasegawa, Izumi ^a   Sakurai, Mayumi ^a   Fujiwara, Kei ^a   Ohno, Tomoyoshi ^a   Ueda, Ryuzo ^a   Mizokami, Masashi ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Fibrosis; Hepatitis C virus; Japanese population; Polymorphism; Transforming growth factor beta 1

Indexed keywords

CYTOKINE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CODON; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 10744223614     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.03161.x     Document Type: Article

References (20)

1. Nishioka K, Watanabe J, Furuta S et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991; 67: 429-33.
2. Friedman SL. Cytokines and fibrogenesis. Semin. Liver Dis. 1999; 19: 129-40.
3. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 1994; 331: 1286-92.
4. Tsushima H, Kawata S, Tamura S et al. Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. J. Hepatol. 1999; 30: 1-7.
5. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014-20.
6. Cambien F, Ricard S, Troesch A et al. Polymorphisms of the transforming growth factor beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas Temoin de'l'infarctus du Myocarde (ECTIM) Study. Hypertension 1996; 28: 881-7.
7. Yamada Y, Miyauchi A, Goto J et al. Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J. Bone Miner. Res. 1998; 13: 1569-76.
8. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29 → C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000; 101: 2783-7.
9. Powell EE, Edwards-Smith CJ, Hay JL et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-33.
10. Gewaltig J, Mangasser-Stephan K, Gartung C, Biesterfeld S, Gressner AM. Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis. Clin. Chim. Acta 2002; 316: 83-94.
11. Ichida F, Tsuji T, Omata M et al. New Inuyama Classification; new criteria for histological assessment of chronic hepatitis. Int. Hepatol. Commun. 1996; 6: 112-19.
12. Wood NA, Thomson SC, Smith RM, Bidwell JL. Identification of human TGF-beta1 signal (leader) sequence polymorphisms by PCR-RFLP. J. Immunol. Meth. 2000; 234: 117-22.
13. Watanabe Y, Kinoshita A, Yamada T et al. A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types of variations in genes for transforming growth factor-beta1 (TGF-beta1) and its signaling pathway. J. Hum. Genet. 2002; 47: 478-83.
14. Niimi T, Sato S, Sugiura Y et al. Transforming growth factor-beta gene polymorphism in sarcoidosis and tuberculosis patients. Int. J. Tuberc. Lung Dis. 2002; 6: 510-15.
15. Vidigal PG, Germer JJ, Zein N. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J. Hepatol. 2002; 36: 271-7.
16. Yamada Y, Fujisawa M, Ando F, Niino N, Tanaka M, Shimokata H. Association of a polymorphism of the transforming growth factor-beta1 gene with blood pressure in Japanese individuals. J. Hum. Genet. 2002; 5: 243-8.
17. Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N. Engl. J. Med. 1991; 324: 933-40.
18. Shirai Y, Kawata S, Tamura S et al. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 1994; 73: 2275-9.
19. Grainger DJ, Heathcote K, Chiano M et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum. Mol. Genet. 1999; 1: 93-7.
20. Tanaka Y, Kanada K, Mizokami M et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc. Natl Acad. Sci. USA 2002; 99: 15584-9.